• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    23andMe Working on New Drug Based on Users’ Genetics

    Danielle Edwards
    Jan. 13, 2020 03:30PM PST
    Pharmaceutical Investing
    BME:ALM

    23andMe is teaming up with Spanish drugmaker Almirall to develop an antibody that treats certain inflammatory diseases using customer data.

    A popular genetic data collection firm may soon offer users more than a family genealogy lesson.

    Privately held personal genomics company 23andMe is teaming up with Spanish drugmaker Almirall (BME:ALM) to develop an antibody that treats certain inflammatory diseases using customer data.

    As a part of the deal, Almirall will get the rights to globally commercialize the antibody, marking the first time 23andMe has licensed a self-developed drug compound.

    The antibody, a large-molecule drug used to target a single protein in the body, was designed to block signals from a family of proteins known as IL-36 cytokine. These proteins have been linked to a variety of inflammatory conditions, like ulcerative colitis and lupus.

    23andMe is most interested in using the compound to treat psoriasis, a condition that can cause red, scaly patches to develop on the skin.

    With the rights to the antibody, Almirall will take the treatment through human clinical trials and to ultimately to the market.

    In an interview with Bloomberg, Emily Drabant Conley, 23andMe’s vice president of business development, called the agreement a “seminal moment” for the company’s work in finding novel drug treatments. “We’ve now gone from database to discovery to developing a drug,” she said.

    23andMe collects the genetic data of consumers who purchase sampling kits in order to learn more about their family’s background and origins.

    According to the collaborating companies, over 10 million kits have been sold, with 80 percent of the participating consumers agreeing to allow their data to be used for research purposes. Based on these numbers, the companies claim to have the world’s largest set of genotypic information, paired with billions of phenotypic data points.

    In a press release, Kenneth Hillan, head of therapeutics at 23andMe, said Almirall’s expertise in medical dermatology was an important consideration when selecting the partnership.

    Almirall has a large drug portfolio for treating a wealth of dermatological conditions, like warts and eczema, and its drugs are sold in over 70 countries worldwide.

    This isn’t the first time 23andMe has used its massive repository of genetic information to develop drugs.

    The firm launched a dedicated therapeutics team in 2015 with the goal of finding ways to use collected data to advance drug development.

    More recently, 23andMe partnered with British multinational pharmaceutical company GlaxoSmithKline (GSK) (NYSE:GSK,LSE:GSK) in 2018 in an exclusive four year collaboration to use its human genetic information for drug target discovery programs. The deal also came with a US$300 million equity investment from GSK.

    Don’t forget to follow @INN_LifeScience for real-time updates!

    Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

    pharmaceutical investingemily drabant conleybme:almlse:gskkenneth hillannyse:gsk
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

    Top 5 Small-cap Pharma Stocks of 2025

    Latest News

    Seegnal Inc. Announces Extension of Maccabi Health Services Contract

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×